BioMarin reports positive preliminary data from Phase I/II trial of BMN 190
Interim data indicates that in all nine of the BMN 190 patients who have been followed for at least six months and up to 15 months, the treatment
Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK.
The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells.
Alirocumab is an investigational monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The marketing application is based on data from more than 5,000 patients, including ten Phase